Ladiratuzumab, CAS 1629760-28-6

Product Description: Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE (HY-15162) to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Trail PA, et al. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. Pharmacol Ther. 2018 Jan;181:126-142. /[2]Li F, et al. Preclinical combinations of the antibody-drug conjugate SGN-LIV1A with chemotherapies show increased activity[J]. Cancer Research, 2016, 76(14_Supplement): 2966-2966.

CAS Number: 1629760-28-6

Molecular Weight: N/A

Compound Purity: 99.76

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Others

• Artikelnummer: MEXHY-P99682-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99682-1
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated